iTeos Therapeutics Unveils Interim Data at ESMO 2024
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company, is at the forefront of developing cutting-edge immuno-oncology therapeutics for patients. The company has announced that interim data from the GALAXIES Lung-201 study, a Phase 2 platform trial sponsored by GSK, will be presented in a late-breaking oral session at the European Society for Medical Oncology (ESMO) Congress 2024. This study focuses on the combination of belrestotug and dostarlimab for patients with previously untreated, unresectable, locally advanced, or metastatic PD-L1 high non-small cell lung cancer (NSCLC).
Details of the Late-Breaking Oral Presentation
The presentation will highlight the interim analysis of the GALAXIES Lung-201 study. The abstract, identified as LBA52, will be part of the Proffered Paper Session: NSCLC Metastatic, which is set to take place in September at 8:30 am CEST / 2:30 am ET.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a pioneering clinical-stage biopharmaceutical firm dedicated to creating innovative immuno-oncology therapies. With a profound understanding of tumor immunology and the mechanisms that suppress immune responses, the company develops novel product candidates. Their pipeline includes clinical-stage programs targeting new immunosuppressive pathways, designed with enhanced pharmacologic properties to improve clinical outcomes. Headquartered in Watertown, MA, iTeos also operates a research center in Gosselies, Belgium.
About Belrestotug
Belrestotug, also known as EOS-448 or GSK4428859A, is a powerful Fc active human IgG1 monoclonal antibody that targets TIGIT, a key inhibitor of immune responses against cancer. This promising therapeutic candidate boosts the antitumor response by interacting with TIGIT and Fc?R, which is crucial for regulating immune responses. Belrestotug is currently advancing through various indications in collaboration with GSK.
Investor Information
iTeos Therapeutics consistently provides vital information for investors in the 'Investors' section of its website at www.iteostherapeutics.com. Investors and potential investors are encouraged to stay informed about the latest developments at iTeos.
Contact Information
Investor Contact:
Carl Mauch
iTeos Therapeutics, Inc.
carl.mauch@iteostherapeutics.com
Media Contact:
media@iteostherapeutics.com
Frequently Asked Questions
What is iTeos Therapeutics known for?
iTeos Therapeutics specializes in developing groundbreaking immuno-oncology therapeutics that aim to enhance patient outcomes.
What is the significance of the GALAXIES Lung-201 study?
The GALAXIES Lung-201 study investigates the effectiveness of a combination therapy for advanced non-small cell lung cancer, which could lead to new treatment strategies.
When will the interim data be presented?
The interim data will be presented during a late-breaking session at the ESMO Congress in September 2024.
What role does GSK play in the study?
GSK serves as the development partner sponsoring the GALAXIES Lung-201 study, supporting the evaluation of the therapeutic combination.
How can investors stay updated on iTeos Therapeutics?
Investors can keep informed by visiting the 'Investors' section on iTeos Therapeutics' official website for the latest news and important updates.